Discussing the potential of Viking therapeutics dual GLP-1/GIP Receptor Agonist, VK2735, in development for obesity and various metabolic disorders with an endocrinologist

Executed on:Apr 20, 2023 4:15 PM EDT

Call Duration:30 minutes

Expert Profile

ExpertBlinded Expert

Institution: ColumbiaAssistant Professor of Medicine in the Division of Endocrinology at Columbia University. 
Manages over 200 patients with obesity and diabetes.
Research expertise in the area of the central regulation of energy balance and metabolism and in the management of pituitary diseases; clinical practice includes neuroendocrinology, reproductive endocrinology, menopause, and the management of weight and metabolic disorders.

Interview Goal

This call will focus on the recently announced positive results from the Phase 1 trial (NCT05203237) of Viking Therapeutics dual GLP-1/GIP Receptor Agonist, VK2735, and it's potential as an oral agent.

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.